Research In Brief
This article was originally published in The Gray Sheet
Executive SummaryGERD endoscopy data still lacking
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.